VIEW AN ABSTRACT

Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial
P. Ošťádal, Fakultní nemocnice v Motole, Kardiologická klinika, Praha, P. Steg, Hôpital Bichat, INSERM U1148, Paris, Y. Poulouin, IT&M Stats, IT&M Stats, Paris, D. Bhatt, Brigham and Women’s Hospital, Heart & Vascular Center, Boston, V. Bittner, University of Alabama at Birmingham, Division of Cardiovascular Disease, Birmingham, T. Chua, Singapore General Hospital, National Heart Centre, Singapore, R. Diaz, Instituto Cardiovascular de Rosario, Estudios Cardiológicos Latino América, Rosario, S. Goodman, University of Alberta, Canadian VIGOUR Centre, Edmonton, Y. Huo, Peking University First Hospital, Peking University First Hospital, Peking, W. Jukema, Leiden University Medical Center, Department of Cardiology, Leiden, Y. Karpov, National Medical Research Centre of Cardiology, National Medical Research Centre of Cardiology, Moscow, R. Pordy, Regeneron Pharmaceuticals, Regeneron Pharmaceuticals, Tarrytown, M. Scemama, Sanofi, Sanofi, Chilly-Mazarin, M. Szarek, State University of New York, Downstate School of Public Health, Brooklyn, H. White, Auckland City Hospital, Green Lane Cardiovascular Services, Auckland, G. Schwartz, University of Colorado School of Medicine, Division of Cardiology, Aurora
Exact citation: Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial. Ostadal P, Steg PG, Poulouin Y, Bhatt DL, Bittner VA, Chua T, Diaz R, Goodman SG, Huo Y, Jukema JW, Karpov Y, Pordy R, Scemama M, Szarek M, White HD, Schwartz GG; ODYSSEY OUTCOMES Investigators. Lancet Diabetes Endocrinol. 2022 May;10(5):330-340. doi: 10.1016/S2213-8587(22)00043-2. Epub 2022 Apr 1.
Impact Factor: 44.867
Published article (PDF file): Otevřít soubor
Type: The Best of Czech Cardiology


generated: 18.06.2024 (05:42)